Table 1.

Clinicopathological Information

Case	Age, years	PSA* [ng/ml] preoperative	PSA* [ng/ml] postoperative	Gleason†	Stage‡
Normal group
N1	52	34.0	n.a.		pT3c, pN0, pMx
N2	65	12.4	0.3		pT2b, pN0, pMx
N3	69	16.0	0.2		pT3a, pN0, pMx
N4	59	1.0	<0.1		pT2b, pN0, pMx
N5	70	58.0	<0.1		pT2b, pN0, pMx
N6	52	3.6	0.2		pT2a, pNx, pMx
N7	44	n.a.	n.a.		pT2a, pN0, pMx
N8	65	8.1	0.9		pT2b, pNx, pMx
N9	62	4.4	<0.1		pT3b, pN0, pMx
Cancer group
T1	66	10.7	<0.1	3 + 3	pT2a, pN0, pMx
T2	63	6.4	0.2	3 + 3	pT3, pN0, pMx
T3	59	27.0	<0.1	4 + 5	pT3b, pN0, pMx
T4	77	59.0	16.1	3 + 4	T3, Nx, M1
T5	62	6.9	<0.1	3 + 4	pT3a, pN0, pMx
T6	69	16.0	0.2	3 + 4	pT3a, pN0, pMx
T7	68	13.3	0.1	3 + 3	pT3a, pN0, pMx
T8	62	59.0	2.2	3 + 4	pT3, pN0, pMx
T9	63	6.1	<0.1	3 + 4	pT2b, pNx, pMx
T10	77	12.8	<0.1	3 + 4	pT3a, pN0, pMx
T11	72	1.5	0.2	4 + 3	pT3b, pN1, pMx
T12	71	48.6	0.7	3 + 4	pT3b, pN0, pMx
T13	65	8.1	0.9	3 + 3	pT2b, pNx, pMx
T14	63	82.0	0.2	5 + 4	pT3b, pN1, pMx
T15	61	34.4	<0.1	4 + 3	pT4, pN0, pMx
T16	62	4.4	<0.1	3 + 4	pT3b, pN0, pMx
T17	64	37.9	0.1	5 + 4	pT4, pN0, pMx

*PSA, prostate specific antigen.

^†Cancer tissue was evaluated according to the histological Gleason scoring system.

^‡Clinical and histopathological (p) staging after prostatectomy according to the TNM classification.

n.a., not available.